Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation

Haruki Uojima^{1

2}, Kazumi Yamasaki³, Masaya Sugiyama⁴, Masayoshi Kage⁵, Norihiro Ishii⁶, Ken Shirabe⁶, Hisashi Hidaka⁷, Chika Kusano⁷, Miyako Murakawa⁸, Yasuhiro Asahina^{8

9}, Takashi Nishimura¹⁰, Hiroko Iijima¹⁰, Kazumasa Sakamoto¹¹, Kiyoaki Ito¹¹, Keisuke Amano¹², Takumi Kawaguchi¹², Nobuharu Tamaki¹³, Masayuki Kurosaki¹³, Takanori Suzuki¹⁴, Kentaro Matsuura¹⁴, Akinobu Taketomi¹⁵, Satoru Joshita¹⁶, Takeji Umemura¹⁶, Sohji Nishina¹⁷, Keisuke Hino^{17

18}, Hidenori Toyoda¹⁹, Hiroshi Yatsuhashi³, Masashi Mizokami²⁰

Affiliations

¹ Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan. lb-uojima@hospk.ncgm.go.jp.
² Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. lb-uojima@hospk.ncgm.go.jp.
³ Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Ōmura, Japan.
⁴ Department of Viral Pathogenesis and Controls, Research Institute, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
⁵ Department of Pathology, Junshin Gakuen University, Fukuoka, Japan.
⁶ Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan.
⁷ Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
⁸ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan.
⁹ Department of Liver Disease Control, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan.
¹⁰ Division of Hepatobiliary and Pancreatic Disease, Department of Gastroenterology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
¹¹ Department of Gastroenterology, Aichi Medical University, Nagakute, Aichi, Japan.
¹² Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-Machi, Kurume, Fukuoka, Japan.
¹³ Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan.
¹⁴ Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
¹⁵ Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
¹⁶ Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
¹⁷ Department of Hepatology and Pancreatology, Kawasaki Medical School, Aichi, Japan.
¹⁸ Digestive Disease Center, Shunan Memorial Hospital, Yamaguchi, Japan.
¹⁹ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
²⁰ Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

PMID: 38625546
DOI: 10.1007/s00535-024-02100-3

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation

Haruki Uojima et al. J Gastroenterol. 2024 Jul.

. 2024 Jul;59(7):598-608.

doi: 10.1007/s00535-024-02100-3. Epub 2024 Apr 16.

Authors

Affiliations

¹ Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan. lb-uojima@hospk.ncgm.go.jp.
² Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. lb-uojima@hospk.ncgm.go.jp.
³ Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Ōmura, Japan.
⁴ Department of Viral Pathogenesis and Controls, Research Institute, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
⁵ Department of Pathology, Junshin Gakuen University, Fukuoka, Japan.
⁶ Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan.
⁷ Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
⁸ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan.
⁹ Department of Liver Disease Control, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan.
¹⁰ Division of Hepatobiliary and Pancreatic Disease, Department of Gastroenterology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
¹¹ Department of Gastroenterology, Aichi Medical University, Nagakute, Aichi, Japan.
¹² Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-Machi, Kurume, Fukuoka, Japan.
¹³ Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan.
¹⁴ Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
¹⁵ Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
¹⁶ Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
¹⁷ Department of Hepatology and Pancreatology, Kawasaki Medical School, Aichi, Japan.
¹⁸ Digestive Disease Center, Shunan Memorial Hospital, Yamaguchi, Japan.
¹⁹ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
²⁰ Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

PMID: 38625546
DOI: 10.1007/s00535-024-02100-3

Abstract

Background: The relationship between liver fibrosis and inflammation and Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with chronic liver disease (CLD) other than hepatitis C remains uncertain, owing to the limitations of qualitative methods. Here, we evaluated the influence of liver fibrosis and inflammation on quantitative M2BPGi (M2BPGi-Qt) in CLD, considering each etiology.

Methods: We recruited 1373 patients with CLD. To evaluate the influence of liver fibrosis and inflammation on M2BPGi-Qt levels, we assessed M2BPGi-Qt levels at each fibrosis and activity stage within different etiologies of CLD based on pathological findings. Subsequently, we evaluated if the accuracy of fibrosis staging based on M2BPGi-Qt could be improved by considering the influence of liver inflammation.

Results: In patients with viral hepatitis, non-alcoholic fatty liver disease, and primary biliary cholangitis, the median M2BPGi-Qt levels increased liver fibrosis progression. Median M2BPGi-Qt levels were not associated with the degree of fibrosis in patients with autoimmune hepatitis (AIH). Median M2BPGi-Qt levels increased with the progression of liver activity in all etiologies. A significant difference was found at each stage in AIH. Considering the liver inflammation, we established an algorithm, M2BPGi-Qt, to determine the alanine aminotransferase-to-platelet ratio (MAP-R) in liver cirrhosis (LC). The area under the receiver operating characteristic curve (AUC) of MAP-R was higher than that of the M2BPGi-Qt for detecting LC (AUC MAP-R = 0.759 and M2BPGi-Qt = 0.700, p < 0.001).

Conclusions: The quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage.

Keywords: Chronic liver disease; Liver fibrosis; Liver inflammation; Noninvasive marker; Quantitative measurement.

PubMed Disclaimer

References

1. Ginès P, Krag A, Abraldes JG, Solà E, et al. Liver cirrhosis. Lancet. 2021;398:1359–76. - DOI - PubMed
1. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017–44. - DOI - PubMed
1. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–15. - DOI - PubMed
1. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76–84. - DOI - PubMed
1. Nah EH, Cho S, Kim S, et al. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J Clin Lab Anal. 2020;34: e23316. - DOI - PubMed - PMC

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation

Affiliations

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical